157665-51-5

Basic information

• Product Name: 3-FLUORO-4-NITROBENZOYL CHLORIDE
• Synonyms: 3-FLUORO-4-NITROBENZOYL CHLORIDE;4-(Chlorocarbonyl)-2-fluoronitrobenzene, 4-(Chloroformyl)-2-fluoronitrobenzene
• CAS NO: 157665-51-5
• Molecular Formula: C₇H₃ClFNO₃
• Molecular Weight: 203.56
• Mol File: 157665-51-5.mol

Chemical Properties

• Melting Point: 23-25
• Appearance: /
• CAS DataBase Reference: 3-FLUORO-4-NITROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-NITROBENZOYL CHLORIDE(157665-51-5)
• EPA Substance Registry System: 3-FLUORO-4-NITROBENZOYL CHLORIDE(157665-51-5)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 157665-51-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-nitrobenzoyl chloride is used as a reactant for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic properties, contributing to the development of novel drugs for treating various medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Fluoro-4-nitrobenzoyl chloride is employed as a reagent in the production of pesticides and other crop protection agents. Its incorporation into these compounds can enhance their effectiveness in controlling pests and diseases, ultimately leading to increased crop yields and improved food security.
Used in Organic Synthesis:
3-Fluoro-4-nitrobenzoyl chloride is also used as a key intermediate in organic synthesis, allowing chemists to create a wide range of specialty chemicals with diverse applications. These can include dyes, polymers, and other materials with specific properties that are valuable in various industries.
Overall, 3-Fluoro-4-nitrobenzoyl chloride is a versatile compound with a broad range of applications across different industries, primarily due to its unique molecular structure and reactivity. Its use as a reactant or reagent in various organic reactions has led to the development of new and innovative products, making it an important component in the fields of pharmaceuticals, agrochemicals, and organic synthesis.

Upstream product

• 79-37-8 oxalyl dichloride 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 

Downstream Products

• 85803-26-5 di-tert-butyl N-(3-fluoro-4-nitrobenzoyl)-l-glutamate 
• 552832-89-0 (3-fluoro-4-nitro-phenyl)-pyrrolidin-1-yl-methanone 
• 939807-28-0 ethyl 3-(3-fluoro-4-nitrophenyl)-3-oxopropanoate 
• 1192720-16-3 N-(2,2-dimethoxyethyl)-3-fluoro-4-nitrobenzamide 
• 2006314-49-2 (R)-1-(3-fluoro-4-nitrophenyl)ethan-1-ol 
• 159390-15-5 4-amino-3-fluorobenzophenone 
• 658700-20-0 N-methyl-3-fluoro-4-nitrobenzamide 

Relevant articles and documents

Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors

Cathepsin K is a major drug target for osteoporosis and related-bone disorders. Using a combination of virtual combinatorial chemistry, QSAR modeling, and molecular docking studies, a series of cathepsin K inhibitors based on N-(functionalized benzoyl)-homocycloleucyl-glycinonitrile scaffold was developed. In order to avoid previous problems of cathepsin K inhibitors associated with lysosomotropism of compounds with basic character that resulted in off-target effects, a weakly- to nonbasic moiety was incorporated into the P3 position. Compounds 5, 6, and 9 were highly selective for cathepsin K when compared with cathepsins L and S, with the Ki values in the 10-30 nM range. The kinetic studies revealed that the new compounds exhibited reversible tight binding to cathepsin K, while the X-ray structural studies showed covalent and noncovalent binding between the nitrile group and the catalytic cysteine (Cys25) site.

Inhibition of Serine Palmitoyltransferase by a Small Organic Molecule Promotes Neuronal Survival after Astrocyte Amyloid Beta 1-42 Injury

Alzheimer's disease (AD) is a slow-progressing disease of the brain characterized by symptoms such as impairment of memory and other cognitive functions. AD is associated with an inflammatory process that involves astrocytes and microglial cells, among other components. Astrocytes are the most abundant type of glial cells in the central nervous system (CNS). They are involved in inducing neuroinflammation. The present study uses astrocyte-neuron cocultures to investigate how ARN14494, a serine palmitoyltransferase (SPT) inhibitor, affects the CNS in terms of anti-inflammation and neuroprotection. SPT is the first rate-limiting enzyme in the de novo ceramide synthesis pathway. Consistent evidence suggests that ceramide is increased in AD brain patients. After β-amyloid 1-42 injury in an in vitro model of AD, ARN14494 inhibits SPT activity and the synthesis of long-chain ceramides and dihydroceramides that are involved in AD progression. In mouse primary cortical astrocytes, ARN14494 prevents the synthesis of proinflammatory cytokines TNFα and IL1β, growth factor TGFβ1, and oxidative stress-related enzymes iNOS and COX2. ARN14494 also exerts neuroprotective properties in primary cortical neurons. ARN14494 decreases neuronal death and caspase-3 activation in neurons, when the neuroinflammation is attenuated in astrocytes. These findings suggest that ARN14494 protects neurons from β-amyloid 1-42 induced neurotoxicity through a variety of mechanisms, including antioxidation, antiapoptosis, and anti-inflammation. SPT inhibition could therefore be a safe therapeutic strategy for ameliorating the pathology of Alzheimer's disease.

sEH Inhibitor or pharmaceutically acceptable composition thereof as well as preparation method and application thereof

The invention provides sEH inhibitor or a pharmaceutically acceptable composition and a preparation method and application thereof, and belongs to the technical field of medicines. sEH Inhibitor or a pharmaceutically acceptable composition thereof according to the present invention is provided, and the sEH inhibitor has the structure shown I. sEH Inhibitor provided by the invention can stabilize an endogenous substance epoxy fatty acid with wide physiological activity, has a strong inhibition effect on human recombinant sEH, and can be used for regulating the generation of a plurality of pro-inflammatory cytokines. The invention relieves the stress of endoplasmic reticulum, prevents or reverses the dysfunction of endothelial dysfunction, stabilizes mitochondria function multiple action mechanisms to obviously relieve neuropathic pain, and can effectively avoid adverse reactions related to the target spot. Furthermore, the sEH inhibitor structure provided by the invention does not contain free carboxyl groups, can avoid adverse reactions such as gastrointestinal irritation caused by oral administration, and is small in adverse reaction, high in bioavailability, excellent in analgesic effect and small in administration amount.

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects an estimated 1 in 50000 individuals worldwide. Until recently, prophylactic HAE treatment options were limited to injectables, a burdensome administration route that has driven the need for an oral treatment. A substantial body of evidence has shown that potent and selective plasma kallikrein inhibitors that block the generation of bradykinin represent a promising approach for the treatment of HAE. Berotralstat (BCX7353, discovered by BioCryst Pharmaceuticals using a structure-guided drug design strategy) is a synthetic plasma kallikrein inhibitor that is potent and highly selective over other structurally related serine proteases. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having successfully completed a Phase III clinical trial (meeting its primary end point) and recently receiving the U.S. Food and Drug Administration's approval for the prophylactic treatment of HAE attacks in patients 12 years and older.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

METHODS OF MAKING HIGH ENANTIOSELECTIVE SECONDARY ALCOHOLS

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The "R-form" compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity, After then, the "S-form" compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

(R)- AND (S)-1-(3-(3-N,N-DIMETHYLAMINOCARBONYL)PHENOXYL-4-NITROPHENYL)-1-ETHYL-N,N'-BIS (ETHYLENE)PHOSPHORAMIDATE, COMPOSITIONS AND METHODS FOR THEIR USE AND PREPARATION

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of

DNA ALKYLATING AGENTS

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Lowering the pKa of a bisimidazoline lead with halogen atoms results in improved activity and selectivity against Trypanosoma brucei in vitro

Diphenyl-based bis(2-iminoimidazolidines) are promising antiprotozoal agents that are curative in mouse models of stage 1 trypanosomiasis but devoid of activity in the late-stage disease, possibly due to poor brain penetration caused by their dicationic nature. We present here a strategy consisting in reducing the pKa of the basic 2-iminoimidazolidine groups though the introduction of chlorophenyl, fluorophenyl and pyridyl ring in the structure of the trypanocidal lead 4-(imidazolidin-2-ylideneamino)-N-(4-(imidazolidin-2-ylideneamino)phenyl)benzamide (1). The new compounds showed reduced pKa values (in the range 1-3 pKa units) for the imidazolidine group linked to the substituted phenyl ring. In vitro activities (EC50) against wild type and resistant strains of T. b. brucei (s427 and B48, respectively) were in the submicromolar range with four compounds being more active and selective than 1 (SI > 340). In particular, the two most potent compounds (3b and 5a) acted approximately 6-times faster than 1 to kill trypanosomes in vitro. No cross-resistance with the diamidine and melaminophenyl class of trypanocides was observed indicating that these compounds represent interesting leads for further in vivo studies.

Substituted benzimidazole derivatives as melanocortin 4 receptor antagonists

The present invention relates to substituted benzimidazole derivatives as melanocortin-4 receptor (MC-4R) modulators.